[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gestational-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gestational-hypertension":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,82,114,145,169,195,226,256,285,315,338,366,391,415,449,472,501,523],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100578685","delivering-hope-helping-women-optimize-prenatal-equity-100578685",false,"NCT06814509","Delivering HOPE (Helping Women Optimize Prenatal Equity)","Inclusion Criteria:\n\n* Aged 16-44 years\n* ≤18 weeks pregnant\n* Speak English, Spanish, or Marshallese\n* Valid email address",true,"FEMALE","16 Years","44 Years",{"count":20,"type":21},1440,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overarching research question is: \"Does the provision of healthy food (Delivering HOPE) during pregnancy reduce the proportion of women who experience excessive gestational weight gain compared with enhanced standard of care (ESoC)?\" To answer this question, the investigators will conduct a large multi-site randomized controlled trial with 1,440 women. Women will be randomized to either the Delivering HOPE arm or the ESoC arm, with approximately 720 participants per arm. Participants randomized to the ESoC arm will receive the standard clinical protocol for nutritional and gestational weight gain counseling recommended for all pregnant women, WIC and SNAP enrollment assistance, referrals to safety net food organizations.Those randomized to the Delivering HOPE arm will be provided the same nutritional and gestational weight gain counseling, WIC and SNAP assistance, and food referrals, as well as a total of $1000\u002F$2000\u002F$3000 (depending on household size) during pregnancy to be used specifically for the purchase of healthy foods recommended in the nutritional counseling. Data for the primary outcome (pre-pregnancy weight and weight at delivery) will be collected from birth records.",[27,28,29,30,31],"Gestational Weight Gain","Diet, Healthy","Gestational Hypertension","Gestational Diabetes","Pregnancy Complications","RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-26","ACTUAL",{"date":38,"type":36},"2025-06-24",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"University of Arkansas","OTHER",8,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100580335","momshome-a-storytelling-based-mobile-health-intervention-to-improve-blood-pressure-management-in-pregnancy-100580335","NCT06835959","Moms@Home: A Storytelling-based Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy","Development of a Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy (Moms@Home)","Moms@Home","Inclusion Criteria:\n\n* Age 18-50\n* English or Spanish speaking\n* A diagnosis of gestational (20-26 weeks gestational age) or chronic hypertension (8-26 weeks gestational age)\n* Singleton or multiple gestation pregnancy,\n* A patient of the University of Massachusetts Memorial Health Obstetrics\u002FMaternal and Fetal Medicine clinics in Worcester, Massachusetts\n* Willing to share home blood pressure monitoring data\n* Comfortable with the use of smartphones and mobile apps\n\nExclusion Criteria:\n\n* Severe hypertension (Systolic blood pressure ≥160 mmHg or Diastolic blood pressure ≥100 mmHg)\n* Current diagnosis of preeclampsia\n* Active substance use\n* Serious physical illness (e.g., unable to interact with a smart device)\n* Enrolled in another home blood pressure monitoring program\n* Excluded from study participation by their provider\n* Inability to provide informed consent\n* Prisoners\u002Finstitutionalized individuals","18 Years","50 Years",{"count":56,"type":21},100,[24],"This pilot study will examine the effects of a digital health approach, Moms@Home, on home blood pressure monitoring in a diverse population of pregnant women with hypertension.",[60,61,29],"Hypertension in Pregnancy","Chronic Hypertension",[63,51,64,65,66,67,68,69,70,71],"Hypertension in pregnancy","Mobile health intervention","Blood pressure","Blood pressure management","Hypertension","Gestational hypertension","Storytelling","Home blood pressure monitoring","Storytelling mobile intervention","2026-06-12",{"date":74,"type":36},"2026-06-16",{"date":76,"type":36},"2025-05-16",{"date":78,"type":21},"2027-11-16",{"name":80,"class":43},"University of Massachusetts, Worcester",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":81},"100537733","phase-4-treatment-with-aspirin-after-preeclampsia-tap-trial-100537733","NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Inclusion Criteria:\n\n* Postpartum individuals ≥18 years old\n* Preeclampsia diagnosis\n\nExclusion Criteria:\n\n* Fetal anomaly\n* Multiple gestation\n* Pre-pregnancy hypertension\n* Allergy or contraindication to low-dose aspirin\n* Pre-pregnancy diabetes","55 Years",{"count":91,"type":21},60,[93],"PHASE4","The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and\u002For microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.",[96,97,67,98,29,99,100,31,101,102,103],"Hypertensive Disorder of Pregnancy","Pre-Eclampsia","Eclampsia","Cardiovascular Diseases","Toxemia","Vascular Diseases","Hypertension, Pregnancy Induced","Hypertension;Pre-Eclamptic",[67],"2026-06-03",{"date":107,"type":36},"2026-06-04",{"date":109,"type":36},"2024-05-29",{"date":111,"type":21},"2027-09-01",{"name":113,"class":43},"Malamo Countouris",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100552062","phase-4-effectiveness-of-two-aspirin-doses-for-prevention-of-hypertensive-disorders-of-pregnancy-aspirin-trial-100552062","NCT06468202","Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL","Comparative Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL","ASPIRIN","Inclusion Criteria:\n\n1. live intrauterine gestation ≤16 6\u002F7 weeks gestational age based on best clinical obstetric estimate,\n2. age 14 years or older and able to provide informed consent,\n3. at least one of the following high-risk criteria: i) any prior pregnancy complicated by preeclampsia ii) current pregnancy complicated by chronic hypertension diagnosed before randomization (ACOG) iii) pre-gestational diabetes (on medication for diabetes prior to pregnancy, or diabetes is diagnosed prior to randomization with hemoglobin A1C of 6.5% or greater or abnormal 3-hour glucose tolerance test) iv) twin gestation (including higher order pregnancy reduced to twins prior to 14 weeks) v) chronic kidney disease vi) autoimmune disease (e.g., antiphospholipid syndrome, systemic lupus erythematous)\n4. or two or more moderate-risk criteria for HDP (per USPSTF), i) nulliparity (no prior delivery at or after 20 weeks 0 days of gestation) ii) obesity (body mass index ≥30 kg\u002Fm2 at time of randomization) iii) age ≥35 years (at time of expected estimated due date) iv) Black race v) low income vi) personal risk factors (previous pregnancy with low birth weight or SGA infant, previous adverse pregnancy outcome \\[unexplained stillbirth\\], placental abruption, interval \\>10 years between pregnancies) vii) Family history of preeclampsia (i.e., mother or sister) viii) In vitro fertilization\n5. patient not currently on aspirin OR patient on aspirin for obstetrical indications (e.g., related to IVF, or HDP) and: i- randomized before 130\u002F7 weeks gestation, or ii- randomized on or after 13 0\u002F7 weeks gestation and started aspirin within 2 weeks prior to randomization (e.g., aspirin started for HDP prevention at 12 0\u002F7 weeks and patient randomized at 13 2\u002F7 weeks).\n\nExclusion Criteria:\n\n1. known allergy or hypersensitivity to aspirin or any medical condition where aspirin is contraindicated (e.g., active peptic ulcer disease, nasal polyps, NSAID-induced asthma, active gastrointestinal bleeding, known G6PD deficiency, severe hepatic dysfunction, bleeding disorders, history of bariatric surgery),\n2. current or planned aspirin use in pregnancy for non-obstetrical indication (e.g., prior stroke\u002Fprior myocardial infraction),\n3. age \\\u003C 14 years,\n4. involuntarily confined or detained,\n5. considered as having a diminished decision-making capacity,\n6. obstetrical ultrasound suspicious for major congenital abnormality, known or suspected fetal aneuploidy, fetal demise, or planned pregnancy termination,\n7. participation in another trial that affects the primary outcome, without prior approval of the PI,\n8. plan to deliver at an outside participating site with inability to obtain medical records,\n9. monoamniotic twin gestation because of the risk of fetal demise and preterm delivery,\n10. participation in this trial in prior pregnancy,\n11. triplet or higher order pregnancy.","14 Years","35 Years",{"count":125,"type":21},10742,[93],"The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg\u002Fday aspirin is superior to 81 mg\u002Fday in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.",[129,130,29],"Hypertensive Disorders of Pregnancy","Preeclampsia",[132,133,134,130],"Hypertensive disorders of pregnancy","Aspirin treatment","Pregnancy","2026-04-28",{"date":137,"type":36},"2026-05-04",{"date":139,"type":36},"2024-10-18",{"date":141,"type":21},"2030-02-01",{"name":143,"class":43},"Ohio State University",16,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":81},"100565848","digital-solutions-to-reduce-maternal-morbidity-and-mortality-in-pregnant-refugee-women-100565848","NCT06647511","Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women","Inclusion Criteria:\n\n* Pregnant\n* Refugee, asylum seeking, or asylee as designated by the U.S. Government\n* Greater than or equal to 18 years of age\n* Has a personal smartphone\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Determined by the PI to be in an extremely vulnerable position and therefore not suited for research participation\n* Planned move from the New York City (NYC) area within the next 24 months",{"count":152,"type":21},75,"OBSERVATIONAL","The goal of this observational study is to use digital health tracking to improve how high blood pressure and other health issues are detected in pregnant refugee women. The main questions this study aims to answer are are:\n\n* Can a digital monitoring system that checks for high blood pressure in these women be tested and refined, using clinical training and validation?\n* Can this digital monitoring system accurately track any related pregnancy health issues and be used to refer participants to care providers?\n* Can this system be used to accurately identify risks associated with the contraction of pregnancy-related conditions, such as preeclampsia and high blood pressure?\n\nParticipants will:\n\n* Complete baseline and follow-up in-person appointments;\n* Complete surveys at these appointment that track their health, stress levels, and comorbidities\u002Frisks associated with pregnancy;\n* Be given a smartwatch fitness tracker and electronic blood pressure cuffs for at-home measurements.",[29],[157,158,159],"refugee","pregnant","digital","2026-04-20",{"date":162,"type":36},"2026-04-22",{"date":164,"type":36},"2024-09-12",{"date":166,"type":21},"2028-09",{"name":168,"class":43},"Weill Medical College of Cornell University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100589338","vagal-stimulation-therapy-and-preeclampsia-100589338","NCT06953115","Vagal Stimulation Therapy and Preeclampsia","Vagal Autonomic Stimulation Physiotherapy (With Trigger Point Release) as an Adjunct to Personalized Antihypertensive Management of Gestational Hypertension Syndrome and Preeclampsia","Inclusion Criteria:\n\n* Outpatient female patients over 18 years old, attending their first appointment and seen in the obstetrics outpatient clinic at the Regional General Hospitals of IMSS Jalisco, with a pregnancy complicated by confirmed mild preeclampsia.\n* No prior treatment.\n* Willing to participate by signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with chronic hypertension.\n* Concomitant organ dysfunction.\n* Immunological diseases.\n* Patients with severe preeclampsia or chronic conditions concomitant with pregnancy.\n* Patients with gestational trophoblastic disease requiring uterine evacuation or choriocarcinoma associated with hypertension.",{"count":177,"type":21},210,[24],"Preeclampsia is one of the most common and serious complications of pregnancy, affecting both the mother and baby. It is a condition characterized by high blood pressure and can lead to severe complications, including neurological issues and reduced blood flow to the placenta. Preeclampsia is responsible for a significant number of maternal and perinatal deaths worldwide, with an estimated 14% of maternal mortality in Mexico linked to this condition.\n\nRecent research suggests that disruptions in the body's autonomic nervous system, specifically the balance between the sympathetic and parasympathetic systems, play a role in the development of preeclampsia. The vagus nerve, which is part of the parasympathetic system, has been shown to regulate inflammation and blood pressure. Stimulating this nerve through pharmacological, magnetic, electrical, or physical therapy techniques has shown promise in preclinical models for improving blood pressure control and reducing complications associated with preeclampsia.\n\nTrigger point release therapy modulates the nervous system by reducing sympathetic activity, promoting blood vessel relaxation, lowering heart rate, and enhancing circulation. When combined with standard antihypertensive treatment, this approach may offer additional benefits for blood pressure regulation.\n\nThis study aims to evaluate the effects of vagal autonomic stimulation physiotherapy using trigger point release therapy as a complementary treatment for pregnant women with preeclampsia. Participants will be randomly assigned to receive either standard antihypertensive treatment with positional release therapy (control group) or the same treatment combined with vagal stimulation physiotherapy (intervention group). Researchers will assess the intervention's effectiveness in controlling blood pressure and improving overall maternal and fetal health outcomes.\n\nBy investigating this non-invasive, drug-free approach, this study aims to offer new strategies for managing preeclampsia, potentially improving maternal and fetal health while reducing reliance on medication.",[29,130],[182,29,97,130,183,184],"Hypertension, Pregnancy-Induced","Physical Therapy Techniques","Modalities, Physical Therapy","2026-04-08",{"date":187,"type":36},"2026-04-09",{"date":189,"type":21},"2026-04-15",{"date":191,"type":21},"2027-06-01",{"name":193,"class":43},"Fundación Internacional René Mey",4,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100596117","phase-2-spironolactone-to-improve-pregnancy-associated-hypertension-trajectories-100596117","NCT07041281","Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories","IMPACT-HT","Inclusion Criteria:\n\n* Females aged ≥18 years\n* HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension\n* BMI ≥25 kg\u002Fm2 prior to pregnancy or in the first trimester\n* Requirement for antihypertensive medication within one week of delivery\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* LV ejection fraction \\\u003C50% or history of clinical heart failure with reduced or preserved ejection fraction\n* Hypertrophic or other genetic cardiomyopathy\n* Hyperkalemia: potassium \\>5.3 mEq\u002FL\n* BMI at screening ≥50 kg\u002Fm2\n* Pre-pregnancy diabetes\n* Estimated glomerular filtration rate (eGFR) \\\u003C60mL\u002Fmin\u002F1.73 m2\n* Cirrhosis\n* Primary aldosteronism\n* Intention to become pregnant within 9 months\n* Active substance abuse\n* Other serious medical illnesses or concerns about protocol adherence\u002F mortality within 9 months\n* Participation in another interventional clinical study\n* Hypersensitivity to spironolactone\n* Addison's disease\n* Concomitant use of eplerenone or finerenone",{"count":203,"type":21},204,[205],"PHASE2","The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight\u002Fobesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight\u002Fobesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.",[130,29],[209,210,211,212,213,214,215],"preeclampsia","gestational hypertension","spironolactone","blood pressure","hypertension","pregnancy","echocardiography","2026-04-02",{"date":218,"type":36},"2026-04-03",{"date":220,"type":36},"2025-10-16",{"date":222,"type":21},"2029-03-02",{"name":224,"class":43},"Massachusetts General Hospital",3,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":81},"100576424","phase-4-a-randomized-placebo-controlled-trial-of-dapagliflozin-dapa-for-cardiovascular-risk-reduction-in-the-postpartum-period-of-hypertensive-pregnancies-hp-100576424","NCT06785116","A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)","A Randomized, Placebo-controlled Trial of DAPAgliflozin for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies","DAPA-HP","Inclusion Criteria:\n\n* Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\\&D unit\n* Determined to be at least 23 and 0\u002F7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery\n* Consents to participation and must understand\u002Fread\u002Fspeak English with the ability to understand and willingness to sign a written informed consent in English\n* Diagnosed with a hypertensive pregnancy by either of the following criteria:\n\n  * Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission\n  * Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record\n  * Antihypertensive\" can be any medication taken for the purpose of blood pressure control per the medical record\n  * A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery\n* Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document.\n* Has two or more blood pressures ≥160\u002F110 Millimeters of mercury (mmHg) at least 60 minutes apart\n\n  * If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg\u002Fml), participants are eligible to participate)\n\nExclusion Criteria:\n\n* Non-English speaking\n* Ongoing pregnancy\n* Stated desire to become pregnant within 8 months post-delivery\n* Intention to breastfeed after enrollment\n* BNP ≥1000 pg\u002Fml within 12 hours of delivery, clinical team to be notified of result\n* Comorbidities that may affect cardiovascular risk assessment (per protocol)\n* Contraindication to dapagliflozin (per protocol)",{"count":235,"type":21},200,[93],"This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery.\n\nEligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily placebo (Control group).\n\nThe study hypothesizes:\n\nThe dapagliflozin group will have higher cardiovascular risk reduction scores than the Control Group.",[29,60,97,239,240],"Superimposed Pre-Eclampsia","Cardiovascular Complication",[242,243,244,245,246],"Medication","Placebo","Postpartum period","Cardiovascular risk reduction","Echocardiogram","2026-03-01",{"date":249,"type":36},"2026-03-04",{"date":251,"type":36},"2025-03-02",{"date":253,"type":21},"2028-08",{"name":255,"class":43},"University of Michigan",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":81},"100619796","evaluation-of-sflt-1plgf-ratio-opg-and-seng-as-predictive-biomarkers-in-the-diagnosis-and-treatment-evaluation-of-preeclampsia-100619796","NCT07349277","Evaluation of sFlt-1\u002FPlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia","Evaluation of sFlt-1\u002FPlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia","PE-POSS","IInclusion Criteria:\n\n* Pregnant women between 20 and 36 weeks of gestation\n* Age between 18 and 45 years\n* Attending the antenatal clinic at the study site\n\nExclusion Criteria:\n\n* Chronic hypertension\n* Renal disease\n* Diabetes mellitus\n* Multiple gestations\n* Autoimmune disorders","45 Years",{"count":266,"type":21},120,"his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1\u002FPlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide",[130,29,129],[270,271,272,273,274,130,275],"sFlt-1\u002FPlGF ratio","Soluble Endoglin (sEng)","Osteoprotegerin (OPG)","Angiogenesis","Placental Dysfunction","methyldopa","2026-01-15",{"date":278,"type":36},"2026-01-20",{"date":280,"type":36},"2025-10-10",{"date":282,"type":21},"2026-04-30",{"name":284,"class":43},"Ammar Jassim Abed",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":81},"100620750","phase-4-lda-and-lmwh-vs-lda-alone-in-high-risk-patients-for-preeclampsia-prevention-100620750","NCT07361679","LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","Combined Administration of Low Molecular Weight Heparin and Aspirin Versus Aspirin Alone in Gravidas at High Risk for Preeclampsia: A Randomized Controlled Trial","preGO","Inclusion Criteria:\n\n* Singleton pregnancy\n* High risk for preeclampsia (risk \\>1:150) based on FMF screening algorithm combining first-trimester ultrasound, biochemical markers, and medical history\n* Gestational age \\\u003C16 weeks at enrollment\n* Maternal age ≥18 years\n* Willing and able to provide written informed consent\n* Adequate ability for follow-up (direct telephone communication, accessible residence)\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Current permanent aspirin use for other medical indications\n* Serious congenital fetal abnormality detected on ultrasound\n* Contraindication to aspirin or low molecular weight heparin including: known hypersensitivity, active peptic ulcer disease, bleeding disorders or coagulopathy, severe thrombocytopenia (platelet count \\\u003C100,000\u002FμL), active or recent significant bleeding, history of heparin-induced thrombocytopenia\n* Pre-existing severe renal failure (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Unable to provide informed consent\n* Low probability of adequate follow-up (residence in remote areas without telephone access, accommodation in temporary structures)",{"count":56,"type":21},[93],"Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.",[297,298,130,31,182,29],"Preeclampsia Severe","Toxemia Of Pregnancy",[209,210,300,301,302,303,304,305,306],"toxemia","Preeclampsia prevention","Low molecular weight heparin","tinzaparin","High-risk pregnancy","LMWH","Maternal-fetal medicine",{"date":308,"type":36},"2026-01-23",{"date":310,"type":36},"2023-01-18",{"date":312,"type":21},"2027-07-01",{"name":314,"class":43},"Alexandra Hospital, Athens, Greece",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":122,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":337},"100491234","the-achieve-trial-achieving-longer-gestation-in-preeclampsia-via-antihypertensive-therapy-100491234","NCT05676476","The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.","Achieve","Inclusion Criteria:\n\n* Pregnant women\n* Gestational age: 23 weeks, 0 days to 35 weeks, 6 days\n* Hypertensive disorder of pregnancy including gestational hypertension or preeclampsia, the non-severe form at enrollment, which is called without severe features by the American College of Obstetricians and Gynecologists.\n* No evidence of the severe form of preeclampsia, termed severe features, as outlined in maternal exclusions\n* No indication for delivery at the time of enrollment.\n* Planned expectant management at time of enrollment\n* Singleton or dichorionic twin gestation, defined at and beyond 14 weeks gestation. (A pregnancy complicated by a vanishing twin in the first trimester defined as less than 14 weeks gestation will be eligible.)\n* Intact membranes\n\nExclusion Criteria:\n\n* Preeclampsia with severe features, defined per ACOG as:\n* Systolic blood pressure of 160 mm Hg or more, or diastolic blood pressure of 110 mm Hg or more on two occasions at least 4 hours apart (unless antihypertensive therapy is initiated before this time)\n* Thrombocytopenia defined as: lower than 100 x 10e9 platelets\u002FL\n* Impaired liver function that is not accounted for by alternative diagnoses and as indicated by abnormally elevated blood concentrations of liver enzymes (to more than twice the upper limit normal concentrations), or by severe persistent right upper quadrant or epigastric pain unresponsive to medications\n* Renal insufficiency (serum creatinine concentration more than 1.1 mg\u002FdL or a doubling of the serum creatinine concentration in the absence of other renal disease)\n* Pulmonary edema\n* New-onset headache unresponsive to medication and not accounted for by alternative diagnoses\n* Visual disturbances\n* Underlying renal dysfunction defined as, presenting the following parameters prior to 20 weeks gestation: baseline creatinine, equal to or higher than, 1.2 mg\u002FdL Or proteinuria: defined as presenting protein in urine, equal to or higher than, 300 mg\u002F24 hours or protein\u002Fcreatinine ratio, equal to or higher than, 0.3 or Urine dipstick reading of greater than or equal to 2 at baseline and in the absence of a urinary tract infection\n* Stage 2 chronic hypertension\n* Contraindications to labetalol and nifedipine XL according to the FDA package insert\n* Patient unable to or unwilling to adhere to management recommendations\n* Fetal Reasons for Study Ineligibility:\n* Fetal growth restriction (lower than 10th percentile) at enrollment, based on an ultrasound within 3 weeks prior to enrollment\n* Oligohydramnios defined by amniotic fluid deepest vertical pocket \\\u003C2 cm based on an ultrasound within the 48 hours prior to enrollment\n* Known major structural or chromosomal abnormality","49 Years",{"count":324,"type":21},132,[24],"The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140\u002F90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.",[130,29,96],"2025-12-08",{"date":330,"type":36},"2025-12-12",{"date":332,"type":36},"2023-02-14",{"date":334,"type":21},"2027-06",{"name":336,"class":43},"University of Alabama at Birmingham",2,{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":15,"sex":345,"minAge":53,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":81},"100534092","peking-university-birth-cohort-in-weifang-pkubc-wf-100534092","NCT06234332","Peking University Birth Cohort in Weifang (PKUBC-WF)","Peking University Birth Cohort in Weifang","Inclusion Criteria:\n\n* Pregnant woman\n\n  1. Pregnant women, 6-13\\^+6 gestational weeks\n  2. Resided in Weifang in the past half years and have no plan to move out after delivery\n  3. Pregnant women who plan to have antenatal care and delivery in Weifang maternal\\&Child Hospital.\n  4. Pregnant women who is willing to participate in this study with informed consent\n* Pregnant woman's husband\n\n  1. His wife was eligible for enrollment\n  2. He is the biological father of the child (his wife's current pregnancy)\n  3. Pregnant women's husband who is willing to participate in this study with informed consent\n* Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study.\n\n  5\\. Before the age of 8 years, his\u002Fher mother provided written informed consent. 6. After 8 years old, he\u002Fshe agreed to continue this study and signed the informed consent.\n\nExclusion Criteria:\n\n* Participants who cannot communicate normally.","ALL",{"count":347,"type":21},2800,"The PKUBC-WF is a prospective cohort study carried out in Weifang city of Shandong, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.",[350,351,30,29,352,353,354,355,356],"Health Problems in Pregnancy","Pregnancy Outcomes","Preterm Birth","Obesity","Mother-Infant Interaction","Child Development","Anemia","2025-11-18",{"date":359,"type":36},"2025-11-24",{"date":361,"type":36},"2024-02-01",{"date":363,"type":21},"2043-12-31",{"name":365,"class":43},"Peking University",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":381,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":4},"100610074","phase-3-cardiovascular-protection-after-preeclampsia-with-enalapril-100610074","NCT07222852","Cardiovascular Protection After Preeclampsia With Enalapril","CAPP-E","Inclusion Criteria:\n\n* Postpartum individuals\n* ≥18 years old\n* Hypertensive disorder of pregnancy\n* Enrolled in Women and Infants Hospital Hypertension Equity remote monitoring program.\n\nExclusion Criteria:\n\n* Maternal cardiac disease\n* Individuals with pre-pregnancy hypertension or diabetes\n* Allergy or contraindication to enalapril",{"count":91,"type":21},[375],"PHASE3","The purpose of this study is to learn if postpartum women are willing to be randomized to different blood pressure medicines after delivery and how that affects blood pressure in women with hypertensive disorders of pregnancy.",[130,96,67,29,378],"Gestational Hypertension After Childbirth",[380],"postpartum hypertension, preeclampsia, gestational hypertension","NOT_YET_RECRUITING","2025-10-29",{"date":384,"type":36},"2025-10-30",{"date":386,"type":21},"2025-11-15",{"date":388,"type":21},"2027-10-15",{"name":390,"class":43},"Women and Infants Hospital of Rhode Island",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":399,"maxAge":54,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":81},"100564684","phase-4-atorvastatin-postpartum-and-reduction-of-cardiovascular-risk-100564684","NCT06632379","AtorvaStatin Postpartum and Reduction of Cardiovascular risK","AtorvaStatin Postpartum and Reduction of Cardiovascular risK (SPARK): A Randomized Placebo-controlled Trial of Atorvastatin Postpartum for Reduction of Cardiovascular Risk","SPARK","Inclusion Criteria:\n\n1. Postpartum\n2. ≥ 20 years old with the ability to give informed consent\n3. Diagnosis of gestational hypertension, preeclampsia prior to delivery admission, or diagnosed with preeclampsia during delivery admission, as determined by clinical team using the American College of Obstetricians and Gynecologists (ACOG) criteria.\n4. English speaking\n\nExclusion Criteria:\n\n1. Individuals who were prescribed an 3-hydroxy-3 methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor prior to or during pregnancy,\n2. Known familial hypercholesterolemia or pre-existing hyperlipidemia, specifically Low-density Lipoprotein (LDL) \\>190 prior to pregnancy or diagnosis of hyperlipidemia with prescription of HMG-CoA reductase inhibitor prior to delivery,\n3. Plan to breastfeed for \\>= 6 months,\n4. Plan for pregnancy conception in the next 6 months,\n5. Incarcerated individuals,\n6. Hypertensive diagnosis thought to be secondary to fetal condition,\n7. Contraindications to HMG-CoA reductase inhibitor therapy or known hypersensitivity to atorvastatin or any component,\n8. Active liver disease (acute hepatitis, chronic active hepatitis, unexplained persistent transaminitis (at least twice upper limit of normal serum transaminases)),\n9. History of rhabdomyolysis or myopathy,\n10. Human Immunodeficiency Virus (HIV) positivity, due to potential interactions between atorvastatin and HIV protease inhibitors,\n11. History of solid organ transplant, due to potential interactions between atorvastatin and immunosuppressants\n12. Active cancer, or\n13. Current use of medications with potential drug interactions, namely cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors, rifampin, and digoxin.","20 Years",{"count":401,"type":21},76,[93],"The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.",[129,130,29],[132,406,134,130],"Atorvastatin treatment","2025-10-15",{"date":409,"type":36},"2025-10-20",{"date":411,"type":36},"2025-10-03",{"date":413,"type":21},"2026-12-15",{"name":143,"class":43},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":225},"100402421","vascular-biomarkers-predictive-of-the-progression-from-hypertensive-disorders-in-pregnancy-to-preeclampsia-in-pregnant-women-100402421","NCT04520048","Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","Exploratory Study. Endothelial Function and Vascular-tropic Biomarkers: Predictive Indicators of the Progression of Hypertensive Disorders in Pregnancy to Pre-eclampsia?","BIOVASC-PreHTA","Inclusion Criteria:\n\n* Patients with a hypertension disorder in pregnancy and\u002For preeclampsia from the 20th amenorrhea week until the 26th ± 2 amenorrhea week.\n* Age between 18 and 40 years old.\n* Having given written consent.\n* Patients affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Presence of pathologies interfering in a major way with vascular parameters: known multicomplicated diabetes treated before pregnancy, hypercholesterolemia known (or LDL\\>130 mg\u002Fdl), multicomplicated connectivitis, proven cardiovascular disease (ischemic heart disease, stroke, arteriopathy of the lower limbs, heart failure), pre-existing known renal failure (serum creatinine \\>125 µmol\u002FL) and\u002For pre-existing proteinuria ≥ 300 mg\u002F24h).\n* Cardiac arrhythmia.\n* Hepatitis C, HIV infection (assay performed within 6 months prior to diagnosis of pre-eclampsia).\n* Recent history of venous (pulmonary embolism, phlebitis) or arterial (myocardial infarction, unstable angina, stroke, transient ischemic attack), thrombotic event ≤ 3 months.\n* Patient already engaged in a therapeutic protocol.\n* Patients under legal protective measures.\n* Patients receiving State Medical Assistance.","40 Years",{"count":425,"type":21},110,[24],"Hypertension during pregnancy remains a leading cause of maternal and fetal morbidity and mortality. The frequency (5 to 10% of pregnancies) and potential severity of these diseases, both for the mother and the child, are reasons for standardizing and optimizing medical practices.\n\nThe cause of hypertension during pregnancy is quite complex, as it depends on a number of factors. Among the hypertensive disorders in pregnancy (HDP), the pathophysiology of pre-eclampsia (one of the most studied in terms of severity) remains poorly understood. The evolution of international guidelines in recent years has made it possible to distinguish various HDP, but schematically we distinguish two main entities by the existence of proteinuria from and after the 20th week of amenorrhea and by maternal-fetal complications, more serious in pre-eclampsia than in gestational hypertension.\n\nAcute placental vasculature and blood flow abnormalities were observed during gestational hypertension and preeclampsia, and maybe due to generalized vascular endothelial activation and vasospasm resulting in systemic hypertension and organ hypoperfusion. Endothelial dysfunction (ED) and abnormal expression of several specific blood biomarkers are now well accepted as characteristics of preeclampsia as a leader.\n\nHowever, the progression of any HDP to preeclampsia is possible, but difficult to predict. By way of example, among between 15 and 40 % of gestational hypertension cases progress to preeclampsia, suggesting that it is the same worsening disease.\n\nED could be pre-existing (chronic, white-coat or masked hypertension) but also at the origin of gestational hypertension (unclassified hypertension, transient pregnancy hypertension), and subsequent development of preeclampsia through an imbalance between pro- and anti-angiogenic factors.\n\nAn imbalance of pro-angiogenic and anti-angiogenic proteins can testify to ED, as can adequate levels of endothelial microparticles.\n\nThe main objective of this research is to assess the presence of urinary endothelial microparticles in stable pregnant women with hypertensive disorder of pregnancy as a marker for the occurrence of pre-eclampsia during pregnancy.",[429,29,97],"Hypertension Disorders in Pregnancy",[431,68,432,433,434,435,436,437,438,439],"Hypertension disorders in pregnancy","Pre-eclampsia","Urinary endothelial microparticules","Endothelial dysfunction","Angiogenic biomarkers","Soluble Fms-like- tyrosine kinase 1","Placental Growth Factor","Vascular Endothelial Growth Factor","Microcirculation","2025-09-05",{"date":442,"type":36},"2025-09-12",{"date":444,"type":36},"2023-08-11",{"date":446,"type":21},"2026-12",{"name":448,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":461,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":81},"100525564","angiogenic-factors-in-the-conservative-management-of-gestational-hypertension-100525564","NCT06123377","Angiogenic Factors in the Conservative Management of Gestational Hypertension","Use of Angiogenic Factors in the Conservative Management of Gestational Hypertension. Prospective, Randomised, Controlled Study.","Inclusion Criteria:\n\n* Pregnant women between 24 and 40 weeks of gestation.\n* Diagnosis of Gestational Hypertension based on ACOG criteria\n* index sFlt-1\u002FPIGF equal or below 33\n\nExclusion Criteria:\n\n* Multiple gestation\n* Maternal vasculitis\n* Previous cesarean section (3 or more)\n* Neurological conditions\n* Chronic renal disease\n* Purpura\n* Heart disease\n* Index sFlt-1\u002FPIGF of 34 or more",{"count":457,"type":21},150,[24],"Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit. One of the most controversial scenarios is gestational hypertension, a group of hypertensive disorders considered the mildest form of the pre-eclamptic spectrum, where current recommendations indicate termination of pregnancy at 37 weeks. However, the decision is based on outdated guidelines developed at a time when angiogenic factors were just beginning to be known. The purpose of the study is to use angiogenic factors as a guide to decide the most appropriate gestational age for termination of pregnancy in patients diagnosed with gestational hypertension.",[29],[68,462],"Angiogenic factors","2025-08-23",{"date":465,"type":36},"2025-08-26",{"date":467,"type":36},"2024-06-01",{"date":469,"type":21},"2026-09-30",{"name":471,"class":43},"Saint Thomas Hospital, Panama",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":381,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":81},"100586834","postpartum-co-rehabilitation-100586834","NCT06920537","Postpartum CO Rehabilitation","Postpartum Cardio-obstetric Rehabilitation After Hypertensive Pregnancy","Inclusion Criteria:\n\n* are 3 to 6 months postpartum, willing, and able to give informed consent for participation;\n* are more than 18 years old;\n* are able to access and use a computer, mobile phone and internet (for online sessions);\n* were diagnosed with GH (BP higher than 139\u002F89 mmHg after 20 gestational weeks) or PE (BP higher than 139\u002F89 mmHg and proteinuria after 20 gestational weeks) during pregnancy.\n\nExclusion Criteria:\n\n* have chronic (pre-existing) hypertension (BP\\>139\u002F89 mmHg pre-pregnancy, \\\u003C20 weeks' gestation or after 6 weeks postpartum);\n* received antihypertensive drug therapy prior to pregnancy or after 6 weeks postpartum;\n* are taking beta-blockers for any reason;\n* participated in exercise activity programs regularly before 3-month postpartum (more than 2 hour of moderate-to-vigorous exercise per week);\n* have any musculoskeletal injury that can limit or contraindicate the practice of exercise;\n* have any major contraindications to exercise such as cardiomyopathy, cardiac arrhythmias and conduction abnormalities or congenital heart disease.",{"count":480,"type":21},40,[24],"Some women who develop high blood pressure during pregnancy, such as gestational hypertension or preeclampsia, may continue to have slightly or moderately high blood pressure after giving birth. This can increase their risk of heart disease later in life. Managing blood pressure and adopting a healthy lifestyle after pregnancy could help lower this risk.\n\nRight now, the investigators don't know much about how postpartum rehabilitation programs focused on heart and pregnancy-related health could help women with these conditions. However, a feasibility study suggests that exercise programs might help reduce blood pressure and encourage healthier lifestyles in these women.\n\nIn this study, the investigators are testing an 8-week exercise program to see how it affects blood pressure, fitness, and blood vessel health. The investigators will compare the results with a group of women who receive usual healthcare, which includes verbal advice on healthy living but no supervised exercise sessions.\n\nThis type of program, called cardio-obstetric rehabilitation, combines exercises for heart health with specialized care for women's health.",[29,484],"Preeclampsia (PE)",[486,487,212,488,210,489,490,491],"postpartum rehabilitation","physical exercise","Pelvic Floor","pre-eclampsia","small vessels","endothelial function","2025-05-12",{"date":494,"type":36},"2025-05-14",{"date":496,"type":21},"2025-06-15",{"date":498,"type":21},"2026-12-30",{"name":500,"class":43},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":81},"100586836","remote-postpartum-blood-pressure-monitoring-and-cardiovascular-education-100586836","NCT06920563","Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education","Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education to Reduce Emergency Department Visits, Re-admissions and Adverse Cardiovascular Outcomes in Hypertensive Disorder of Pregnancy","Inclusion Criteria:\n\n1. Age of at least 18 years.\n2. Postpartum status.\n3. Experience new-onset hypertension during pregnancy.\n4. Enrollment in Connected MOM.\n5. Ability to provide informed consent.\n6. Establish medical care within the Ochsner System to facilitate data collection.\n\nExclusion Criteria:\n\n1. History of preeclampsia or gestational hypertension during previous pregnancy\n2. History of chronic hypertension\n3. History of coronary artery disease (myocardial infarction, coronary stent placement, coronary artery bypass grafting, spontaneous coronary artery dissection)\n4. History of ischemic CVA\n5. History of Congestive heart failure\n6. Renal dysfunction\n7. Liver dysfunction\n8. Left ventricular dysfunction\n9. Congenital heart disease\n10. Still birth at delivery",{"count":509,"type":21},296,[24],"The goal of this clinical trial is to learn if patient education and regular text reminders are a feasible intervention to engage patients and reduce post partum hypertension. The main questions it aims to answer are:\n\nIs a structured postpartum remote blood pressure monitoring intervention with education and individualized medication initiation\u002Fadjustment follow-up by televisit feasible? Does a structured program reduce the occurrence of postpartum hypertension, ED visits, hospital readmissions, and adverse outcomes?\n\nParticipants will:\n\nView an educational video on HDP post-delivery Receive 1-2 times daily text messages for 6 weeks postpartum Have their blood pressure medications adjusted to lower targets post partum",[513,29],"Pre-Eclampsia; Complicating Pregnancy","2025-04-01",{"date":516,"type":36},"2025-04-09",{"date":518,"type":36},"2025-03-17",{"date":520,"type":21},"2026-10-16",{"name":522,"class":43},"Ochsner Health System",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":81},"100507521","physical-activity-and-cardiovascular-profile-of-pre-conceptional-women-at-risk-for-ghd-100507521","NCT05888467","Physical Activity and Cardiovascular Profile of Pre-conceptional Women At Risk for GHD","The Impact of Physical Activity on the Cardiovascular Profile of Pre-conceptional Women At Risk for Developing Gestational Hypertensive Disorders in Subsequent Pregnancy.","SPORTY","Inclusion Criteria:\n\n* Women at risk for the development of GHD in subsequent pregnancy based on the presence of at least one of the following risk factors:\n\n  * high body mass index (BMI\\>30 kg\u002Fm²)\n  * a family history of PE (mother, sister)\n  * in the need of assisted reproduction techniques in a previous or subsequent pregnancy\n  * maternal comorbidities: prior PE, diabetes mellitus, chronic hypertension, chronic kidney disease or antiphospholipid syndrome\n* Non-pregnant (as confirmed by a negative pregnancy urine dipstick test)\n* Age ≥ 18 years\n* Being able to understand the Dutch language\n\nExclusion Criteria:\n\nParticipants eligible for this study must not meet any of the following criteria:\n\n* Pregnant at inclusion\n* Not being able to exercise according to physician's decision\n* Suffering from underlying diseases that can affect the CV profile such as oncological diseases coronary heart disease, aortic disease, peripheral arterial disease\n* Participating in another clinical study that may alter the results of this study",{"count":532,"type":21},140,[24],"To compare the cardiovascular profile of pre-conceptional women at risk for developing Gestational Hypertensive Disorders in subsequent pregnancy before and after physical activity.",[29,536],"Cardiovascular Pregnancy Complication","2025-03-21",{"date":539,"type":36},"2025-03-26",{"date":541,"type":36},"2023-05-15",{"date":543,"type":21},"2025-12",{"name":545,"class":43},"Hasselt University"]